ClinicalTrials.gg
CompletedNCT02803268Updated Dec 22, 2025

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

A Phase 1 interventional study of MT-8554 low dose and MT-8554 middle dose in Vasomotor Symptoms, sponsored by Tanabe Pharma Corporation. Completed at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Tanabe Pharma Corporation · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

02

Conditions studied

  • Vasomotor Symptoms
03

In context

Lead sponsor

Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet one of the following criteria:Woman aged ≥18 years with proven non- breast cancer (Stages I, II or III) and without evidence of disease / Woman aged ≥40 years who are / Woman aged ≥40 years who are peri-menopausal
  • Subjects who have ≥7 Vasomotor Symptoms per day on average
  • A body weight of ≥45 kg

Exclusion criteria

Exclusion Criteria:

  • Participation in more than three clinical studies involving administration of an unlicensed Medicinal Product in the previous year, or any study within 12 weeks
  • endocrine, thyroid, hepatic, respiratory, gastro-intestinal, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder
  • Clinically relevant abnormal medical history, physical findings or laboratory values
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    MT-8554 low dose

    Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.

    Drug: MT-8554 low dose · Drug: Placebo

  • Experimental
    MT-8554 middle dose

    Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.

    Drug: MT-8554 middle dose · Drug: Placebo

  • Experimental
    MT-8554 high dose

    Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.

    Drug: MT-8554 high dose · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as measured by vital signs

    Time frame: Up to Day 21

  2. Safety and Tolerability as measured by number of participants with adverse events

    Time frame: Up to Day 21

Secondary outcomes

  1. Plasma concentration of MT-8554 after dosing

    Time frame: Up to Day 15

  2. Change from baseline in core body temperature

    Time frame: Up to Day 14

  3. Frequency of Vasomotor Symptoms

    Time frame: Up to Day 15

07

Study locations

1 site
  • Investigational center
    City Name, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jan 2017 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2016
First posted
Jun 16, 2016
Start
Jun 2016
Primary completionActual
Jan 2017
CompletionActual
Jan 2017
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02803268
Responsible party
Sponsor
First posted
Jun 16, 2016
Start date
Jun 2016
Primary completion
Jan 2017
Completion
Jan 2017
Last update
Dec 22, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion